Vinorelbine and Prednisone in older Cancer Patients with Hormone-Refractory Metastatic Prostate Cancer a Phase II Study

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Tumori

• Publication date

  2003-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/030089160308900106PMID 12729357
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemotherapy for advanced prostate cancer.

  2005cited by this paper
• Cancer of the prostate

  2003cited by this paper
• A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer.

  2002cited by this paper
• The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study.

  2001cited by this paper
• A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer.

  2001cited by this paper
• A practical approach to the older patient with cancer.

  2001cited by this paper
• Vinorelbine and estramustine in androgen‐independent metastatic prostate cancer

  2000cited by this paper
• Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial.

  1999cited by this paper
• Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

  1999cited by this paper
• Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer.

  1999cited by this paper
• Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

  1999cited by this paper
• Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor

  1999cited by this paper
• Hormone-refractory prostate cancer: an evolving standard of care.

  1999cited by this paper
• Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.

  1998cited by this paper
• Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points.

  1998cited by this paper
• Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.

  1998cited by this paper
• Management of hormone refractory prostate cancer: current standards and future prospects.

  1998cited by this paper
• Cancer statistics, 1997

  1997cited by this paper
• Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer.

  1997cited by this paper
• Epidemiology of cancer in the elderly. Current status and projections for the future.

  1997cited by this paper
• Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.

  1997cited by this paper
• Vinorelbine (Navelbine): a third-generation vinca alkaloid.

  1997cited by this paper
• Vinorelbine: an overview.

  1996cited by this paper
• Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

  1996cited by this paper
• Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer.

  1996cited by this paper
• Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.

  1996cited by this paper
• New agents in the therapy of hormone-refractory patients with prostate cancer.

  1995cited by this paper
• The national institute on aging and the national cancer institute seer collaborative study on comorbidity and early diagnosis of cancer in the elderly

  1994cited by this paper
• Management of cancer of the prostate.

  1994cited by this paper
• Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancer

  1993cited by this paper
• Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.

  1993cited by this paper
• Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.

  1992cited by this paper
• Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.

  1992cited by this paper
• Cancer statistics

  1989cited by this paper
• Malpractice Claims: New Data and New Trends

  1979cited by this paper
• The McGill Pain Questionnaire: Major properties and scoring methods

  1975cited by this paper
• [Prostatic carcinoma].

  1966cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine

  2022cites this paper
• Chemotherapy in frail elderly patients with hormone-refractory prostate cancer: A “real world” experience

  2016cites this paper
• Weekly administration of docetaxel and epirubicin as first-line treatment for hormone-refractory prostate carcinoma.

  2009cites this paper
• Assessing outcomes in prostate cancer clinical trials

  2008cites this paper
• Vinorelbine, Doxorubicin, and Prednisone in Hormone Refractory Prostate Cancer

  2008cites this paper
• A Dose Escalation Study of Biweekly Oral Vinorelbine and Gemcitabine in Patients with Solid Tumors

  2007cites this paper
• A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.

  2007cites this paper
• Vinorelbine, doxorubicin, and prednisone in androgen‐independent prostate cancer

  2006cites this paper
• Hoosier Oncology Group Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis

  2006cites this paper
• Weekly paclitaxel and epirubicin in the treatment of symptomatic hormone-refractory advanced prostate carcinoma: report of a phase II trial

  2005cites this paper
• Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate.

  2005cites this paper
• Treatment Options in Hormone-refractory Metastatic Prostate Carcinoma

  2004cites this paper
• Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer.

  2004cites this paper
• Original article Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer

  2004cites this paper
• Weekly paclitaxel and epirubicin in the treatment of symptomatic hormone-refractory advanced prostate carcinoma: report of a phase II trial

  2004cites this paper
• A modified low-dose regimen of mitoxantrone and prednisolone in patients with androgen-independent prostate cancer.

  2004cites this paper